PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Symptom | |bone metastases |
| Sentences | 122 |
| PubMedID- 21882211 | Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. |
| PubMedID- 22670199 | A 69-year-old man was diagnosed as having advanced prostate cancer with multiple bone metastases, and when diagnosed, his psa was 1,149 ng/ml. |
| PubMedID- 22293499 | Study on the distribution features of bone metastases in prostate cancer. |
| PubMedID- 23049278 | Recently, nnt analyses were performed using skeletal-related event data from two phase iii clinical trials comparing denosumab with zoledronic acid for treating bone metastases in patients with castration-resistant prostate cancer or other solid tumors (excluding breast cancer).89 these analyses determined the nnt required to avoid a single skeletal-related event during continuous, long-term denosumab therapy in patients with castration-resistant prostate cancer or other solid tumors. |
| PubMedID- 22528368 | Therapeutic strategies for bone metastases in prostate cancer can palliate pain, delay/prevent skeletal complications, and prolong survival. |
| PubMedID- 24396515 | 68gaga-dota-toc was found valuable for therapy planning and accurate diagnosis of multiple endocrine neoplasia 184, sudden onset of vision problems 183, duodenopancreatic net 182, autoimmune thyroid disease like graves' disease and hashimoto's disease 191. patients affected by prostate cancer with bone metastases were examined with 68gaga-dota-toc 192. however, due to the low expression of sstr2 and sstr5 the uptake in the lesions was low and the signal was weak. |
| PubMedID- 26033416 | Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases. |
| PubMedID- 21625400 | In one clinical study, combination therapy using docetaxel and zoledronic acid, a bisphosphonate that inhibits osteoclastic activity, was administered to prostate cancer patients with bone metastases.109 patients that responded to the therapy had a 35% decrease in overall serum il-6 levels, while patients that did not respond had a 76% increase in serum il-6 levels.109 a confounding variable in this finding is that some of the increase in serum il-6 may be due to a stress response to the chemotherapeutic agents themselves, and the high levels of il-6 may actually confer drug resistance.110 however, il-6 has also been correlated to c-reactive protein (crp) levels in the serum, and reduction in crp levels alone may indicate positive biologic effects of chemotherapeutics indicated by a reduction in serum il-6.111,112 although there is a dearth of clinical studies using il-6 as a predictive biomarker of therapeutic response, initial studies support the concept that changes in serum cytokine levels such as il-6 are worthy of more investigation. |
| PubMedID- 21942303 | Background: bone metastases are common in patients with hormone-refractory prostate cancer. |
| PubMedID- 20829534 | Purpose: to prospectively investigate and monitor the response to antiandrogen treatment of bone metastases in patients with prostate cancer by using diffusion-weighted (dw) magnetic resonance (mr) imaging with the apparent diffusion coefficient (adc) and functional diffusion maps (dms). |
| PubMedID- 26097628 | This vertebral venous system has been well documented as a pathway of paradoxical metastasis, as in bone metastases in patients with prostate cancer and breast cancer, which were also described by baston . |
| PubMedID- 25364402 | Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: a case report. |
| PubMedID- 25832466 | Limited numbers of patients who had castrate-resistant prostate cancer with osteoblastic bone metastases were enrolled into a phase 0 trial with biology-driven endpoints. |
| PubMedID- 23234632 | Denosumab treatment of prostate cancer with bone metastases and increased urine n-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase ii trial. |
| PubMedID- 26450096 | Moreover radium-223-dichloride can improve overall survival and the time to the first symptomatic skeletal event in castration-resistant prostate cancer patients with bone metastases. |
| PubMedID- 22576683 | We previously reported that advanced prostate cancer (pca) patients with multiple distant bone metastases had markedly decreased serum alpha2m levels (<20 mg/dl) and no detection of alpha2m by immunoelectrophoresis (defined as alpha2m deficiency). |
| PubMedID- 23861598 | Even-sapir et al17 found that pet using naf is a very sensitive tool for the detection of bone metastases in patients with high-risk prostate cancer, with reported sensitivity, specificity, and positive and negative predictive values of 100%, 62%, 74%, and 100%, respectively. |
| PubMedID- 26216391 | Radium-223 dichloride ((223)ra) is an alpha particle emitter and a natural bone-seeking radionuclide that is currently used for treating osteoblastic bone metastases associated with prostate cancer. |
| PubMedID- 24371684 | Dasatinib is a small molecular multi-tyrosine kinase inhibitor of the src-family kinases (among other targets), and has shown efficacy in prostate cancer with bone metastases. |
| PubMedID- 22888655 | Based on above results we recommend for breast cancer and prostate cancer patients with bone metastases and life expectancy more than 3 months the irradiation with 19.5 gy given by 3 fractions. |
| PubMedID- 25075962 | Cooperation among physicians involved in cancer management will lead to improvements in the treatment of bone metastases due to prostate cancer and is thought to extend to other tumor types. |
| PubMedID- 20681408 | Bisphosphonates are well-established agents for treating skeletal-related events (sres) in prostate cancer patients with bone metastases. |